Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 379-383

  Prados, Jose ^a   Melguizo, Consolación ^a   Marchal, Juan Antonio ^b   Vélez, Celia ^a   Alvarez, Luis ^b   Aránega, Antonia ^b  

^a UNIVERSITY OF ALMERÍA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ; DACTINOMYCIN; DESMIN; DOXORUBICIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR DIFFERENTIATION;

EID: 0032579361     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19980130)75:3<379::aid-ijc9>3.0.co;2-%23     Document Type: Article

References (29)

1. AGUANNO, S., BOUCHÉ, M., ADAMO, S. and MOLINARO, M., 12-O-Tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line. Cancer Res., 50, 3377-3382 (1990).
2. BATES, S.E., MICKLEY, L.A. and CHEN, N., Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol. cell. Biol. 9, 4337-4344 (1989).
3. BECK, W.T. and DANKS, M.K., Multidrug resistance in tumor cells. In: I.B. Roninson (ed.), Molecular and cellular biology, pp. 3-46, Plenum, New York (1991).
4. BROWN, R., Gene amplification and drug resistance. J. Pathol., 69, 287-292 (1991).
5. D'AMORE, E.S.G., TOLLOT, M., STRACCA-PANSA, V., MENEGON, A., MELI, S., CARLI, M. and NINFO, V., Therapy associated differentiation in rhabdomyosarcomas. Mod. Pathol., 7, 69-75 (1994).
6. FUQUA, S.A.W., FITZGERALD, S.D. and MCGUIRE, W.L., A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. Biotechniques, 9, 206-211 (1990).
7. GARBEROGLIO, C., DUDAS, M., CASPER, E.S., BERTINO, J. and CORDONCARDO, C., Expression of P-glycoprotein in normal muscle cells and myogenic tumors. Arch. Pathol. Lab. Med., 116, 1055-1061 (1992).
8. GERMAN, U.A., P-glycoprotein - a mediator of multidrug resistance in tumour cells. Europ. J. Cancer, 32, 927-944 (1996).
9. GOLDSTEIN, L.J., MDR1 gene expression in solid tumours. Europ. J. Cancer, 32, 1039-1050 (1996).
10. MANANIA, N., BOYANO, M.D., MANGIN, C. and POUPON, M.F., Oncogene and mdr1 gene expression in rat rhabdomyosarcoma sublines of different metastatic potential. Anticancer Res., 11, 473-480 (1991).
11. HAKKISON, D.J., Molecular mechanisms of drug resistance in tumours. J. Pathol., 175, 7-12 (1995).
12. KANDEL, R.A., CAMPBELL. S., NOBLE-TOPHAM, S., BELL, R. and ANDRULIS, I.L., Correlation of P-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Diagn. mol. Pathol., 4, 54-65 (1995).
13. KAMI, S.B., P-glycoprotein and drug resistance-time for reappraisal? Brit. J. Cancer, 67, 641-643 (1993).
14. LEHNERT, M., Clinical multidrug resistance in cancer: a multifactorial problem. Europ. J. Cancer, 32, 412-420 (1996).
15. LOE, D.W., DEELEY, R.G. and COLE, S.P.C., Biology of the multidrug resistance-associated protein. MRP. Europ. J. Cancer, 32, 927-444 (1946).
16. LOLLINI, P.L., GIOVANNI, C., BRUNELLA, D.R., LANDUZZI, L., NICOLETTI, G., PRODI, G., SCOTLANDI, K. and NANNI, P., Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res., 49, 3631-3636 (1984).
17. MANIATIS, T., FRITSCH, E. and SAMBROOK, J., Molecular cloning, a laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1982).
18. MAURER, H.M., BELTANGADY, M., GEHAN, E.A., CRIST, W., HAMMOND, D., HAYS, D.M., HEYN, R., LAWRENCE, W., NEWTON, W. and ORTEGA, J., The intergroup rhubdomyosarcoma study - I. A final report. Cancer, 61, 209-220 (1988).
19. MELGUIZO, C., PRADOS, J., FERNÁNDEZ, J.E., VÉLEZ, C., ALVAREZ, L. and ARÁNEGA, A,. Myogenic differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. J. Pathol., 175, 23-29 (1995).
20. MELGUIZO, C., PRADOS, J., MARCHAL, J.A., ARÁNEGA, A.E., ALVAREZ, L. and ARÁNEGA, A,. Low concentrations of actinomycin D cause potentially therapeutic differentiation in human rhabdomyosarcoma cell line RD. Pathol. Res. Pract., 192, 188-194 (1996).
21. PAPPO, A.S., Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr. Opin. Oncol., 7, 361-366 (1995).
22. PAPPO, A.S., SHAPIRO, D.N., CRIST, W.N. and MAURER, H.M., Biology and therapy of pediatric rhabdomyosarcomas. J. clin. Oncol., 13, 2123-2139 (1995).
23. RAMANI, P. and DEWCHAND, H., Expression of mdr1/P-glycoprotein and pi 10 in neuroblastoma. J. Pathol., 175, 13-22 (1995).
24. SCHEPER, R.J., BULTE, J.W.M., BRAKKEE, J.G.P., QUAK, J.J., VAN DER SCHOOT, E., BALM, A.J.M., MEUER, C.J., BROXTERMAN, H.J., KUIPLR, C.M., LANKELMA, J. and PINEDO, H.M., Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glyeoprotcin associated with multidrug-resistance. Int. J. Cancer, 42, 389-394 (1988).
25. THRIKAINEN, M.I. and KRUSIUS, T., Multidrug resistance. Ann. Med., 23, 509-520 (1991).
26. TISHLER, D.M. and RAFFEL, C., Development of multidrug resistance in a primitive nouroectodermal tumor cell line. J. Neurosurg., 76, 502-506 (1992).
27. VERGIER, B., CANY, L., BONNET, F., ROBERT, J., DE MASCAREL, A. and COINDRE, J.M., Expression of MDR/P-glscoprotein in human sarcomas. Brit. J. Cancer. 68, 1221-1226 (1993).
28. WAXMAN, S., BORDEN, E.C., LOTAN, R., LEVENS, D. and YOUNG, C.W., Differentiation therapy of cancer: laboratory and clinical investigations. Cancer Res., 53, 4109-4115 (1993).
29. WU, L., SMYTHE, A.M., STINSON, S.F., MULLENDORF, L.A., MONKS, A., SCUDEIRO, D.A., PAULL, K.D., KOUTSOUKOS, A.D., RUBINSTEIN, L.V., BOYD, R.B. and SHOEMAKER, R.H., Multidrug-resistance phenotspe of diseaseoriented panels of human minor cell line used for anticancer drug screening. Cancer Res., 52, 3029-3034 (1992).